Emerging drugs for hyperlipidemia

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

(2010) Frederick J Raal et al.   LANCET

Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia

(2010) Paul W. Ladenson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Flushing Profile of Extended-Release Niacin/Laropiprant Versus Gradually Titrated Niacin Extended-Release in Patients With Dyslipidemia With and Without Ischemic Cardiovascular Disease

(2009) Darbie Maccubbin et al.   AMERICAN JOURNAL OF CARDIOLOGY

Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE−/− Mice

(2009) Heather Fraser et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial

(2009) Robert S Rosenson et al.   LANCET

Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study

(2009) Robert R Henry et al.   LANCET

Statin Therapy with Ezetimibe or Niacin in High-Risk Patients

(2009) John J.P. Kastelein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Extended-Release Niacin or Ezetimibe and Carotid Intima–Media Thickness

(2009) Allen J. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

(2008) Daniel Bloomfield et al.   AMERICAN HEART JOURNAL

The Residual Risk Reduction Initiative: A Call to Action to Reduce Residual Vascular Risk in Patients with Dyslipidemia

(2008) Jean-Charles Fruchart et al.   AMERICAN JOURNAL OF CARDIOLOGY

Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity

(2008) Menno Vergeer et al.   CIRCULATION

Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis

(2008) Stephen J. Nicholls et al.   CIRCULATION

New approaches to target microsomal triglyceride transfer protein

(2008) Mohammed Mahmood Hussain et al.   CURRENT OPINION IN LIPIDOLOGY

Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

(2008) J. D. Brunzell et al.   DIABETES CARE

Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia

(2008) D. Maccubbin et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The synergistic inhibition of atherogenesis in apoE−/−mice between pravastatin and the sPLA2inhibitor varespladib (A-002)

(2008) Zory Shaposhnik et al.   JOURNAL OF LIPID RESEARCH

PCSK9: a convertase that coordinates LDL catabolism

(2008) Jay D. Horton et al.   JOURNAL OF LIPID RESEARCH

Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial

(2008) Jean-Claude Tardif et al.   LANCET

Statins and diabetes – Authors' reply

(2008) Patricia M Kearney et al.   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of the antioxidant succinobucol (AGI-1067) on human atherosclerosis in a randomized clinical trial

(2007) Jean-Claude Tardif et al.   ATHEROSCLEROSIS